Tonix Pharmaceuticals Holding Corp. (TNXP)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 1
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3, and the 20-day average dollar volume of ~$4.64M is below the $5,000,000 liquidity floor; the chart offers no bullish setup either — 2.88 is below every moving average with MACD negative, ADX 67.68 in a downtrend, and a fresh 52-week low at 2.81. No pullback/oversold limit is viable (price is already at a new low with no support beneath it) and no breakout stop is viable (nearest settled levels 3.08 and 3.25 sit inside a falling MA stack).
Company overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics and diagnostics. Its pipeline includes treatments for immunology, rare diseases, infectious diseases, and CNS disorders, with key candidates like TNX-1500 for organ transplant rejection and TNX-102 SL for fibromyalgia.
Fundamental
very weakTonix faces substantial going-concern risks with high cash burn and dilution, despite real revenue growth from its TONMYA launch.
Tonix has a real launch story — TTM revenue near $43 million, an 86.9% gross margin and TONMYA scaling quickly — but it also discloses explicit substantial going-concern doubt, burned $125.6 million of operating cash in nine months of 2026, has runway only into early Q3 2027, funds itself through continuous at-the-market issuance that swelled the share count by about 52% in 2026, and now faces a Paragraph IV patent challenge to TONMYA. Revenue growth does not yet offset the burn, and per-share value keeps deteriorating; the fundamentals are speculative and high-risk rather than merely uncertain.
Sentiment
very weakMedia sentiment is mildly positive but flat, with no forward catalysts and retail sentiment unmeasured.
Tonix's Q3 2026 print (announced, 2026-11-09) is the dominant first-party catalyst and the tape scored it positively — TONMYA net sales of about $15M, up 37% sequentially, 166M covered lives and $163M cash — but the media delta versus the 30–90-day baseline is determinate yet flat (polarity_score of roughly +0.19 improving to roughly +0.27, a move inside the ±0.1 flat band, not an improvement), and the Red-Flag Screen is not clean: a severe going-concern / auditor-doubt flag is live from an auditor going-concern explanatory paragraph in the FY2025 10-K and an explicit substantial-doubt conclusion in the Q3 2026 10-Q, so the severe red-flag cap is applied. No forward-dated catalyst sits inside the next 30 trading days and retail is unmeasured (Reddit access blocked).
Technical
very weakThe stock is in a strong downtrend, trading below all moving averages with no bullish setup.
Score 1 of 5 — broken structure, not merely weak. Price 2.88 sits 39% below SMA20 (4.72), 62% below SMA50 (7.51) and 75% below SMA200 (11.72), and every short-lookback average in the suite (EMA9 3.83, EMA21 4.85, WMA9 3.62, WMA21 4.35, DEMA14 3.18, TEMA14 3.13) is above the tape and still falling. ADX14 at 67.68 with price beneath all averages is an extreme-strength DOWN trend read, not a bullish one; ADX is direction-agnostic and here it confirms the direction of the decline. MACD (-1.16 line / -1.11 signal / -0.05 histogram) remains deeply negative and the histogram has rolled back over from +0.15 on 11-04 to -0.05, so the late-October reflex bounce has already failed. RSI14 11.04 and Williams %R -97.41 flag a capitulation-grade extension, but in a name down from ~$14 in late August to $2.88, deeply oversold is a description of the descent rather than a reversal signal — there is no higher low, no base and no momentum reclaim to trade against. No bullish setup qualifies.
You’re looking at 2026-11-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

